TD Cowen lowered the firm’s price target on Tandem Diabetes to $22 from $34 and keeps an Outperform rating on the shares. The firm noted the company lowered full-year OUS sales guidance as the revision reflects new disruption reported by OUS distributors relating to new launches and to a new reimbursement agreement in France.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes price target lowered to $25 from $40 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $32 at Baird
- Tandem Diabetes price target lowered to $21 from $30 at Wells Fargo
- Tandem Diabetes names Mark Novara as EVP and Chief Commercial Officer
- Tandem Diabetes cuts FY23 revenue to ‘at least’ $765M from at ‘least’ $785M
